TrialInvestigational new drugs2018

A phase 2 study of OSI-906 (linsitinib, an insulin-like growth factor receptor-1 inhibitor) in patients with asymptomatic or mildly symptomatic (non-opioid requiring) metastatic castrate resistant prostate cancer (CRPC).

Pedro Barata et al.PubMed ↗Publisher ↗

No numbers read from the abstract.